Skip to main content

Drug Repurposing: Testing a Drug Approved for One Disease for Its Efficacy in Another

July 20, 2017

In this webinar, we talk about why we need to test these drugs in Parkinson's, how they're identified and go through some in the pipeline.

Webinar Details


Thursday, July 20, 2017


1 hr


12:00 pm ET

  • MJFF offers Continuing Medical Education (CME) credit for practicing health care professionals for each Third Thursday Webinar. Click the link in the Resource List after viewing the webinar to take the post-test survey and receive your CME credit.

    Date of Original Release: July 20, 2017
    Date CME Credit No Longer Available: July 20, 2019

    Learning Objectives

    At the conclusion of this course, participants should be able to: 

    1. Define drug repurposing. 
    2. Describe how drugs are chosen for repurposing. 
    3. Discuss why drugs need to be tested in a new patient population. 
    4. Summarize where repurposed drugs are in clinical testing for Parkinson's disease.
    Target Audience

    This educational activity is designed for primary care physicians, family practice physicians, general medicine physicians, geriatricians, general neurologists, movement disorder specialists and any other health care practitioners who manage patients with Parkinson's disease.


    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and The Michael J. Fox Foundation for Parkinson's Research. The Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

    Oakstone Publishing, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing, LLC's planners, content reviewers, and editorial staff disclose no relevant commercial interests.


    Dave Iverson
    Nothing to disclose

    Todd Sherer, PhD
    Chief Executive Officer
    The Michael J. Fox Foundation
    Wife is employed at Pfizer

    Sabrina Paganoni
    Assistant Professor
    Harvard Medical School
    Nothing to disclose

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.